OncoZenge (ONCOZ) Q4 2024 earnings summary

Executive summary

• Focus during Q4 was on partnership opportunities for European commercialization; a non-binding agreement with Molteni Farmaceutici for Europe was signed after the period.

• A SEK 30.2 million investment agreement with Sichuan Yangtian Bio-Pharmaceutical was signed, pending new share issues in 2025.

• BupiZenge™ is prepared for a pivotal phase 3 study for EU approval, with positive EMA feedback and strong stability data.

• No revenue generated; cost reductions achieved through staff departures and tight cost control.

Financial highlights

• Q4 2024: Net sales SEK 0k (0), operating result SEK -2,501k (-3,170), EPS SEK -0.21 (-0.27).

• Full year 2024: Net sales SEK 0k (0), operating result SEK -8,685k (-15,902), EPS SEK -0.74 (-1.36).

• Cash flow for the year SEK -8,764k (-16,513); cash and cash equivalents at year-end SEK 3,863k (12,627).

• Equity at year-end SEK 9,950k (18,641); equity per share SEK 0.85 (1.59); solidity 87.02% (91.65%).

• No dividend proposed for 2024.

Outlook and guidance

• Financing is contingent on the planned directed share issues in 2025.

• The company aims for EU market approval and commercial launch of BupiZenge™ in collaboration with Molteni.

• Phase 3 study preparation is advanced, with a possible EU launch in 2026.

• Strategic focus on global opportunities, including the US and China, with new investor support.